ProLySis.co.uk
Title
Prolysis - a research and development company
Description
"Novel antibacterial compounds and an urgent medical need create a win-win commercial opportunity"
Prolysis is an antibacterial drug discovery and development company with new classes of compounds in pre-clinical development. Novel antibacterial drugs are urgently needed to treat hospital-acquired and community-associated infections where existing therapies are failing due to antibiotic resistance.
Our cost-effective business model combines our internal expertise in bacterial cell biology with structural biology, cheminformatics and medicinal chemistry from our technology partners. This has enabled Prolysis to create a multi-project, pre-clinical portfolio. Prolysis will commercialise its new antibacterial drugs by out-licensing after demonstrating proof-of-concept in human studies.
Additional Information
- Anthracis
- Anthrax
- Anti Infective
- Anti Microbial
- Antibacterial
- Antibiotics
- Assays
- Bacillus Subtilis
- Bacteria
- Bio Terrorism
- Biodefence
- Biodefense
- Biotechnology
- Biotechnology And Pharmaceuticals
- Broad Spectrum
- Business
- Career
- Chemical
- Clinical
- Combinatorial
- Developing
- Development
- Discovery
- Drug Discovery
- Essential
- Evotec Oai
- Functional
- Genomics
- Hts
- High Throughput Screening
- Infections
- Jobs
- Kill Assays
- Life Threatening
- Manufacturing
- Medicinal Chemistry
- Novel
- Oxford
- Oxfordshire
- Pathogens
- Pathology
- Pharmaceutical
- Pharmaceuticals
- Professor Jeff Errington
- Professor Jeffrey Errington
- Prolysis
- Proprietary
- Research
- Resistance
- Resistant
- Screening
- Serious
- Sir William Dunn School
- Small Molecule Drugs
- Staphylococcus
- Staphylococcus Aureus
- Structure Based Drug Design
- Target Discovery
- Uk
- University Of Oxford
- Anti-infective
- Anti-microbial
- Bio-terrorism
- Biotechnology and Pharmaceuticals
- Evotec OAI
- HTS
- UK